SCHEMBL3192263

SCHEMBL3192263

CC(=N)Nc1ccc2oc(Cc3ccccc3)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
LMNA P02545 2/20 0.41
TSHR P16473 1/20 0.41
NPY1R P25929 1/20 0.41
MAPK1 P28482 1/20 0.41
AKT1 P31749 1/20 0.41
HTT P42858 1/20 0.41
GPR55 Q9Y2T6 2/20 0.39
RAB9A P51151 4/20 0.38
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
NPC1 O15118 2/20 0.36
HPGD P15428 2/20 0.36
POLB P06746 1/20 0.36
HSD17B10 Q99714 2/20 0.36
STS P08842 1/20 0.36
TP53 P04637 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3205824 0.88 F10 (0.45) ALDH1A1KDM4ERAB9AF2F10
SCHEMBL8177216 0.79 HSD17B10 (0.50) ALDH1A1KDM4ELMNATSHRMAPK1
SCHEMBL3190423 0.77 MAPT (0.52) ALDH1A1KDM4ELMNATSHRRAB9A
SCHEMBL3184553 0.77 MAOB (0.55) ALDH1A1KDM4ENPY1RRAB9ASMN1; SMN2
SCHEMBL3205818 0.75 ALDH1A1 (0.39) ALDH1A1KDM4ELMNARAB9ASMN1; SMN2
SCHEMBL15157277 0.74 MAOA (0.49) ALDH1A1KDM4ELMNATSHRNPY1R
SCHEMBL3191877 0.74 HDAC1 (0.44) ALDH1A1KDM4ELMNARAB9AMAPT
SCHEMBL11619290 0.73 CYP1A2 (0.46) LMNATSHRNPY1RMAPK1AKT1
SCHEMBL3205800 0.73 APP (0.52) ALDH1A1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL3205802 0.73 APP (0.52) ALDH1A1KDM4ERAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120802-A1 Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production MAKOVEC FRANCESCO 2010-05-13 US disclosed
US-7674809-B2 Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production ROTTAPHARM S.P.A. (IT) 2010-03-09 US disclosed
US-20050197331-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production ROTTAPHARM SPA 2005-09-08 US disclosed
EP-1571142-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production Rottapharm S.p.A. (IT) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120802-A1 Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production NOS3, NOS1, NOS2 ALDH1A1 1195/4885KDM4E 3052/4885LMNA 2950/4885
US-20050197331-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production NOS3, NOS1, NOS2 ALDH1A1 1195/4885KDM4E 3052/4885LMNA 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.